MENU
+Compare
NBIX
Stock ticker: NASDAQ
AS OF
Jun 26, 03:12 PM (EDT)
Price
$126.41
Change
-$1.77 (-1.38%)
Capitalization
13.72B

NBIX Neurocrine Biosciences Forecast, Technical & Fundamental Analysis

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States... Show more

Industry: #Biotechnology
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NBIX with price predictions
Jun 25, 2025

Aroon Indicator for NBIX shows an upward move is likely

NBIX's Aroon Indicator triggered a bullish signal on June 25, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 259 similar instances where the Aroon Indicator showed a similar pattern. In of the 259 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 18, 2025. You may want to consider a long position or call options on NBIX as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for NBIX moved out of overbought territory on June 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for NBIX turned negative on May 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NBIX broke above its upper Bollinger Band on June 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.297) is normal, around the industry mean (62.463). P/E Ratio (57.202) is within average values for comparable stocks, (89.614). Projected Growth (PEG Ratio) (0.464) is also within normal values, averaging (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (19.198).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

View a ticker or compare two or three
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NBIX is expected to report earnings to rise 39.77% to 97 cents per share on August 05

Neurocrine Biosciences NBIX Stock Earnings Reports
Q2'25
Est.
$0.98
Q1'25
Missed
by $0.07
Q4'24
Beat
by $0.12
Q3'24
Beat
by $0.29
Q2'24
Beat
by $0.50
The last earnings report on May 05 showed earnings per share of 69 cents, missing the estimate of 76 cents. With 66.29K shares outstanding, the current market capitalization sits at 13.72B.
A.I. Advisor
published General Information

General Information

a product based biopharmaceutical company

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12780 El Camino Real
Phone
+1 858 617-7600
Employees
1400
Web
https://www.neurocrine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AUUD4.350.01
+0.23%
Auddia Inc
FTLF12.81-0.03
-0.23%
FitLife Brands Inc
EHAB9.40-0.11
-1.16%
Enhabit
PCOR67.51-0.81
-1.19%
Procore Technologies
CPK120.29-3.83
-3.09%
Chesapeake Utilities

NBIX and Stocks

Correlation & Price change

A.I.dvisor tells us that NBIX and LFCR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and LFCR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
-0.31%
LFCR - NBIX
32%
Poorly correlated
+0.72%
EOLS - NBIX
30%
Poorly correlated
-5.41%
CGC - NBIX
29%
Poorly correlated
-1.60%
ELAN - NBIX
28%
Poorly correlated
+1.85%
HROW - NBIX
27%
Poorly correlated
-0.50%
More